Comparison of dialysate- and plasma clearences between three different haemodialysis modes.

Comparison of dialysate- and plasma clearences between three different haemodialysis modes. - Comparison of clearence between different haemodialysis modes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31119

Enrollment

Registered

2008-05-20

Start date

2007-11-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

haemodialysis treatment with artificial kidney

Interventions

Treatment 1: Low-flux haemodialysis Qb: 350ml/min Qd: 700ml/min. Temp: 36°C Gambro AK 200 Ultra S Gambro Polyflux 17 L 4 hours Nadoparin: 1st shot and 2nd shot after 2 hours. Treatment 2: High-flux

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Dialysis patients > 18 years of age. Dialysis > 3 months. Signed informed consent. Uncomplicated hemodialysis. AV fistula with flow > 350ml/min. Residual function

Exclusion criteria

Exclusion criteria: Instable dialysis No bleeding tendency. No informed consent.

Design outcomes

Primary

Measure	Time frame
Dialysate samples: Samples collected: continuously and separated in aliquots every hour. Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin. Blood samples: Before start treatment: Haemoglobin, Haematocrit, Albumin, CRP. Before and during treatment: Samples collected: before treatment, every hour and at treatment end. Before artificial kidney and just before venous return. (i.e. after post dilution substitution) Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin, Albumin, Haematocrit. Once every type of treatment: D-dimeer en TAT as measures of degree of clotting in the artificial kidney. Before and after treatment. Anti- Xa as measure of activity of Nadoparin. Before and after treatment. C3D as measure of complement activation. After treatment.	—

Measure

Time frame

Dialysate samples: Samples collected: continuously and separated in aliquots every hour. Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin. Blood samples: Before start treatment: Haemoglobin, Haematocrit, Albumin, CRP. Before and during treatment: Samples collected: before treatment, every hour and at treatment end. Before artificial kidney and just before venous return. (i.e. after post dilution substitution) Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin, Albumin, Haematocrit. Once every type of treatment: D-dimeer en TAT as measures of degree of clotting in the artificial kidney. Before and after treatment. Anti- Xa as measure of activity of Nadoparin. Before and after treatment. C3D as measure of complement activation. After treatment.

—

Secondary

Measure	Time frame
- Diascan measurement on the Gambro AK 200-Ultra S.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)